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Abstract: Hyperprolactinemia is a common endocrinological disorder that may be caused by 
several physiological and pathological conditions. Several drugs may determine a signiﬁ  cant 
increase in prolactin serum concentration that is frequently associated with symptoms. The 
so-called typical antipsychotics are frequently responsible for drug-related hyperprolactinemia. 
Risperidone is one of the atypical neuroleptics most likely to induce hyperprolactinemia, while 
other atypical drugs are unfrequenlty and only transiently associated with increase of prolactin 
levels. Women are more sensitive than men to the hyperprolactinemic effect of antipsychotics. 
Classical and risperidone-induced hyperprolactinemia may be revert when a gradual antipsy-
chotic drug discontinuation is combined with olanzapine or clozapine initiation. Antidepressant 
drugs with serotoninergic activity, including selective serotonin reuptake inhibitors (SSRI), 
monoamine oxidase inhibitors (MAO-I) and some tricyclics, can cause hyperprolactinemia. 
A long list of other compounds may determine an increase in prolactin levels, including pro-
kinetics, opiates, estrogens, anti-androgens, anti-hypertensive drugs, H2-receptor antagonists, 
anti-convulsivants and cholinomimetics. Finally, hyperprolactinemia has also been documented 
during conditioning and after autologous blood stem-cell transplantation and during chemo-
therapy, even though disturbances of prolactin seem to occur less frequently than impairments 
of the hypothalamus-pituitary-gonad/thyroid axis after intensive treatment and blood marrow 
transplantation.
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Regulation of prolactin secretion
Prolactin (PRL) is a 23 kDa polypeptide hormone secreted by the lactotroph cells of the 
anterior pituitary gland. It is released with a circadian trend, in 4 to 14 daily secretory 
pulses of increasing amplitude after sleep onset, with a decline short after waking and 
nadir around noon. Prolactin secretion responds to physiological stimuli: it increases 
after food intake and breast mechanical stimulation. Prolactin main biological role is 
milk induction and lactation, but it probably exerts also metabolic effects and takes 
part in reproductive mammary development, parental behavior (Benker et al 1990) 
and immune responsiveness stimulation (Halbreich et al 2003).
Even though monomeric 23 kDa form is predominant, big variants of 50 kDa and 
prolactin-IgG complexes of 150 kDa, with high immunogenic properties but poor 
biological effects, can circulate in large amount (up to 85% of total prolactin). This 
condition, referred to as “macroprolactinemia”, is characterized by normal levels of 
biological prolactin and lack of clinical symptoms (Gibney et al 2005).
Accurate deﬁ  nition of normal prolactin serum concentration can be difﬁ  cult, 
because of high inter-individual variability and the frequent occurrence of “macro-
prolactinemia”, that can be revealed by polyethylene glycol precipitation of serum 
samples (Suliman et al 2003).
Prolactin homeostasis is the result of a complex balance between positive and nega-
tive stimuli, derivating from both external and endogenous environment. A plenty of 
mediators, of central, pituitary and peripheral origin (Freeman et al 2000, Figure 1), Therapeutics and Clinical Risk Management 2007:3(5) 930
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take part in regulating prolactin secretion, through a direct 
or indirect effect on lactotroph cells.
The main physiologic control of prolactin secretion is 
exerted by the inhibiting action of dopamine. Dopamine, 
secreted in hypothalamic periventricular zone (periventricu-
lar nucleus and arcuates nucleus) and released from neuronal 
projections in the median eminence, reaches the anterior 
pituitary gland through portal vessels (system known as 
“tuberoinfundibular dopamine pathway” or “TIDA”). The 
dopamine-mediated inhibition of prolactin secretion occurs 
through the binding of D2 receptors on the membrane of 
lactotroph cells and involves several signal transduction 
systems, resulting in inhibition of prolactin gene transcrip-
tion, reduction of prolactin synthesis and release.
Other prolactin inhibiting factors of CNS derivation 
include GABA, somatostatin, acetylcholine and norepine-
phine; an autocrine regulation is exerted by prolactin through 
a short loop negative feedback on its own release, by stimu-
lating TIDA cells through prolactin receptors binding, while 
GH, TGFβ1 and endothelin have a paracrine regulating role 
at pituitary level.
Prolactin secretion mostly results from removal of 
dopamine inhibiting pathway. Hence, most “prolactin-relasing 
factors (PRFs)” act indirectly trhough the disactivation of 
TIDA system, though direct effects on the lactotrophs and 
other mechanisms of action, not completely clariﬁ  ed, are 
certainly present.
Serotonin physiologically mediates nocturnal surges 
and suckling-induced prolactin rises and is a potent, though 
indirect, modulator of prolactin secretion. The serotoninergic 
neurons project from the dorsal raphe nucleus to the medial 
basal hypothalamus and exert their action via 5HT1A and 
5HT2 receptors mechanisms; Paraventricular Nucleus (one 
of the prominent nuclei of the Medial Hypothalamus), proved 
by pharmacologic and anatomic data to be a major regulatory 
site of serotonin-induced prolactin release, contains differ-
ent populations of neurosecretory cells, producing oxytocin, 
vasopressin, vasoactive intestinal peptide (VIP), thyreotropin 
releasing hormone (TRH) and other neuropeptides. It is 
known that serotonin affects prolactin levels through the 
action of one or more of these PRFs, among which VIP path-
way is the best studied. VIP (and a fragment of its precursor 
named peptide his-isoleucine) acts both via hypothalamic 
afferents and direct paracrine and autocrine mechanisms, 
through lactotroph cell receptors binding, enhancing adenyl-
ate cyclase activity and increasing prolactin gene transcrip-
tion. Oxytocin seems to participate in VIP-induced prolactin 
release and may act through the inhibition of TIDA. However, 
there is little synaptic contact between serotonin-ﬁ  bers and 
dopamine cells. Hence, if direct inhibition of dopamine cells 
occurs, it is rather through serotonin volume transmission. A 
larger body of evidence of direct stimulation of GABAergic 
neurons in the vicinity of dopamine cells exists. This path-
way, referred to as “tuberoinfundibular-GABA (TI-GABA) 
system”, has been shown to modulate prolactin secretion 
in humans, possibly through serotoninergic stimulation of 
GABA interneurons (that express the 5HT1A membrane 
receptor) resulting in inhibition of TIDA cells and prolactin 
secretion (Emiliano and Fudge 2004).
TRH physiologic role is unresolved, but it is thought 
to stimulate both prolactin gene expression (via protein 
kinase C pathway) and prolactin release from anterior 
pituitary.
Estrogens modulate prolactin secretion in response to 
reproductive events through different mechanisms: ampliﬁ  ca-
tion of mitotic activity of the lactotrophs, enhancement of pro-
lactin gene transcription and translation through ERβ-receptor 
binding, indirect simulation of prolactin synthesis through VIP 
and OT gene expression enhancement. Estrogens have also an 
indirect stimulating action on prolactin release through inhibi-
tion of hypothalamic dopamine synthesis and reduction in the 
number of pituitary D2 receptors. The net effect is an elevation 
of prolactin levels through increase in amplitude of prolactin 
bursts, release and storage (Halbreich et al 2003).
Histamine has a predominantly stimulatory effect, due to 
the inhibition of the dopaminergic system, which is mediated 
via H2-receptors following central administration and via H1-
receptors following systemic infusion. During blockade of 
the receptor mediating the stimulatory effect, histamine may 
also exert a minor inhibitory effect on prolactin secretion, 
which involves transmitters other than dopamine and is medi-
ated via H1-receptors following central administration and 
via H2-receptors following systemic administration (Knigge 
1990). Histamine-induced prolactin production is mediated 
by dopaminergic as well as serotoninergic neurons, but other 
PRFs (eg, beta-endorphin, VIP, vasopressin or TRH) may 
be involved (Knigge 1990).
Opioids regulate prolactin secretion through unknown 
mechanisms, perhaps acting on the synchronization of 
pulsatile pattern of prolactin (Lafuente 1994) and may have 
a role in stress-induced hyperprolactinemic response (Van 
Vugt and Meites 1980; Benker et al 1990).
A number of other neurotrasmitters and neuropep-
tides can also modulate prolactin secretion, among which 
galanin, endothelin, TGFbeta1, angiotensin, somatostatin, 
substance P, neurotensin, calcitonin, EGF, natriuretic Therapeutics and Clinical Risk Management 2007:3(5) 931
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atrial peptide, bombesin, colecistokinine, acetylcholine, 
vasopressin (Figure 1).
Hyperprolactinemia, usually deﬁ  ned as fasting levels 
at least 2 hours after waking above 20 ng/ml in men and 
above 25 ng/ml in women (Halbreich et al 2003), is one 
of the most common endocrinologic disorders of the 
hypothalamic-pituitary axis.
Several physiologic and pathologic conditions can 
result in increased plasma prolactin levels (Table 1): during 
pregnancy, prolactin is secreted under estrogen stimuli 
INHIBITING FACTORS STIMULATING FACTORS
Dopamine
GABA   ACh  Calcitonin
Neurotensin   SSH
5-HT  Cathecolamines CNS
TRH Vasopressin Neurotensin
Opioids Angiotensin II VIP
Substance P Galanin Gastrin
CCK NO Oxytocin
VIP Galanin
Angiotensin II EGF
AMSH PRL ACh
TGFB1 Endothelin
GH
Leptin E2 Peripheral
organs
T3    Progesterone
Glucocorticoids
PRL
Figure 1 Major agents regulating prolactin secretion.
Table 1 Major physiologic and pathologic causes of hyperprolactinemia
Physiologic Pathologic
  Pituitary disorders  CNS disorders  Systemic diseases
Pregnancy   Prolactinomas   Tumors  Severe Hypothyroidism
Breast feeding  Mixed pituitary  Granulomatous   Epathic cirrhosis
Breast stimulation  adenomas  diseases  Chronic renal 
Sleep  Cushing’s disease  Vascular disorders  failure
Stress  Acromegaly  Autoimmune disorders  Polycystic ovary
  Not secreting adenomas  Hypothalamic tumours  syndrome
  Empty sella syndrome  or metastasis  Estrogen-secreting
  Pituitary stalk section  Cranial irradiation  tumours
 or  tumours  Seizures  Pseudocyesis
  Lymphoid hypophysitis    Chest wall trauma
     Herpes  zooster
Adapted from Molitch 1992Therapeutics and Clinical Risk Management 2007:3(5) 932
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and induces lactation; prolactin is a major stress-induced 
hormone, and its secretion follows psychological, environ-
mental or physical stress; conditions of impaired prolactin 
metabolism are advanced liver dysfunction or chronic renal 
failure. Among central nervous system diseases, the most 
common are anterior pituitary disorders (above all prolactin-
secreting adenomas, but also GH-secreting adenomas and 
empty sella syndrome), and any space – occupying lesion 
involving hypothalamus (meningiomas, craniopharingiomas, 
sarcoidosis, vascular impairments) or disrupting pituitary 
stalk connection; systemic diseases, such as severe hypothy-
roidism, epathic cirrhosis, chronic renal failure, polycystic 
ovary syndrome, estrogenic tumors from granulosa cells 
(Santala et al 2001), pseudocyesis.
Most symptoms of hyperprolactinemia involve the repro-
ductive system and are due to both a direct action of prolactin 
on target tissues and indirect effects mediated by the decrease 
in gonadotropin pulsatile secretion, that leads to gonadal 
dysfunction. The most frequent symptoms of chronic hyper-
prolactinemia include reproductive dysfunction (anovulation, 
menstrual irregularity, sub-fertility, decreased estrogen and 
testosterone production), sexual impairment (diminished 
libido, erectile dysfunction, retrograde or painful ejaculation, 
orgasmic dysfunction, impotence), breast pathology (galac-
torrhea, breast enlargement, possible prolactin – sensitive 
dysplasia with increased risk for breast cancer), abnormali-
ties associated with chronic hypogonadism (decreased bone 
mineral density and osteoporosis, increased cardiovascular 
risk), behavioral and mood alterations (depression, anxiety, 
hostility, memory deﬁ  cit, psychosis) (Kinon et al 2003b), 
possible immunologic depression (Halbreich et al 2003).
Drug-induced hyperprolactinemia
Pharmacologic hyperprolactinemia is a problem of underes-
timated prevalence. This is due to lack of externally visible 
symptoms, patients’ reluctance for embarrassing disturbs 
and/or clinicians’ lack of awareness.
A large group of medications can raise prolactin 
levels (Table 2 and Figure 2): drugs variably able of 
impairing central nervous system (CNS) dopaminergic 
function, such as false dopamine precursors, inhibitors 
of L-aromatic aminoacids decarboxylase and dopamine 
receptor antagonists, drugs enhancing serotoninergic 
neurotransmission, such as serotoninergic precursors, 
direct and indirect serotonin agonists and blockers of 
serotonin reuptake, histamine H2 receptor antagonists 
(Steiner et al 1976; Polleri et al 1980; Muller et al 1983; 
Di Renzo et al 1989; Molitch 2005).
Most of the above mentioned medications lead to an 
increase in prolactin plasma concentration through an 
inﬂ  uence on prolactin secretion control, primarily removing 
inhibitor pathways or directly stimulating prolactin produc-
tion by the lactotroph cells.
In a pharmacoepidemiological analysis conducted on 
French Pharmacovigilance Database, recording 182,836 
adverse drug reactions from 1985 to 2000, Petit et al reported 
159 cases of hyperprolactinaemia (Petit et al 2003). In that 
study (Petit et al 2003), the female/male ratio was 5.9 (136 
women and 29 men) and mean age was 40 (range 14–85) years. 
The rates of hyperprolactinaemia according to therapeutic drug 
classes were as follow: 31% were associated with neuroleptics, 
28% with neuroleptic-like drugs, 26% with antidepressants, 
5% with H2-receptor antagonists, and 10% with other drugs 
(Petit et al 2003). Among the latter group, veralipride, a ben-
zamide derivated with anti-dopaminergic action (Vercellini 
et al 1994), indoramin (Pradalier et al 1998) and sertraline 
are reported in the literature as inducing hyperprolactinemia.
Psychotropic drugs
Antipsychotics
Antipsychotics are the most common cause of pharmacologic 
hyperprolactinemia, and the majority of antipsychotic agents 
cause hyperprolactinemia (Molitch 2005).
The early age of onset of schizophrenia and related disor-
ders and the need for long-term therapy make antipsychotic 
Table 2 Drugs inducing sustained hyperprolactinemia
Antipsychotics
Typical
Haloperidol Chlorpromazine,
Thioridazine, Thiothixene
Atypical
Risperidone, Amisulpride
Molindone, Zotepine
Antidepressants
Tricyclics
Amitriptyline, Desipramine 
Clomipramine
Amoxapine
SSRI Sertraline, Fluoxetine, Paroxetine
MAO-I Pargyline, Clorgyline
Other
Psychotropics
Buspirone
Alprazolam
Prokinetics Metoclopramide, Domperidone
Antihypertensive Alpha-methyldopa, Reserpine, 
Verapamil
Opiates Morphine
H2 Antagonists Cimetidine, Ranitidine
Others Fenﬂ  uramine, Physostigmine
Chemotherapics
Note: Only drugs with demonstrated ability to induce hyperprolactinemia above 
the normal range have been included in this table.Therapeutics and Clinical Risk Management 2007:3(5) 933
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chronic adverse effects, such as hyperprolactinemia, a major 
therapeutic problem (Halbreich and Kahn 2003).
In female schizophrenic patients, menstrual irregulari-
ties can be partly due to an illness-related dysfunction of the 
hypothalamic-pituitary-gonadal axis with subsequent hypoes-
trogenic state (Haddad and Wieck 2004) and to abnormali-
ties of neurotransmitters or their receptors, including D1, D2 
serotoninergic alfa1 e 2, histamine, GABA and sigma opiates 
(Goldstein SR 1999). However, since the prolactin secretory 
pattern of drug-free psychiatric patients, measured throughout 
the day, is not different from that observed in healthy control 
subjects, the elevation of baseline prolactin in treated psychi-
atric patients seems to be more related to drug effects rather 
than to the illness itself (Haddad and Wieck 2004).
During the last ten years, a new class of neuroleptic 
drugs, usually referred to as “atypical antipsychotics”, has 
been developing, to avoid the side effects related to the 
complete dopaminergic blockade exerted by the oldest drugs 
(extrapyramidal symptoms and hyperprolactinemia). Actu-
ally, neither receptorial binding characteristics, nor clinical 
criteria, enable a clear cut deﬁ  nition of “atypical” behavior, 
a possibility being a positive relation between antipsychotic 
efﬁ  cacy and degree of side effects due to antagonism of other 
dopamine pathways (Kuhn et al 2000).
In this regard, classiﬁ  cation of antipsychotic drugs may 
be based on their prolactin-elevating aptitude: classical 
antipsychotics are traditionally “prolactin-raising”, while 
the newest class is usually “prolactin-sparing”.
A study of 422 psychotic patients on neuroleptic treat-
ment showed that antipsychotic therapy is strongly associ-
ated with hyperprolactinemia, with a signiﬁ  cantly higher 
prevalence of hyperprolactinemia in classic antipsychotics-
treated patients compared to the “atypical”-treated group 
(Montgomery et al 2004). Furthermore, neuroleptic-induced 
hyperprolactinemia is often a dose-related side effect (Smith 
et al 2002; Montgomery et al 2004).
The extent of prolactin increase is not only dependent 
on drug characteristics (ie, class of antipsychotic and dose 
administered), but also on patient’s sex and age. Clinical con-
sequences associated with hyperprolactinemia are well docu-
Lactotroph
Pituitary Cells
Hypothalamus
DOPAMINE  SEROTONIN
SYNTHESIS
PERIPHERAL 
ACTIVITY
False Precursors
Alphametyldopa
Decarboxylase Inhibitors
Carbidopa, Benserazide
Others
Verapamil, Opiates, Estrogens
Storage Depletors 
Reserpine
H2 Antagonists
Cimetidine, Ranitidine
Opiates
Receptorial Antagonists
Classical antipsychotics
Atypical antipsychotics
Amoxapine, Buspirone 
Metoclopramide, Domperidone
Labetalol
SYNTHESIS
and
RELEASE
PERIPHERAL 
ACTIVITY
Precursors
Tryptophan and 5HT
Others
Fenfluramine
Receptorial
Agonists
Quipazine, Buspirone
Fenfluramine
Aripiprazole, Ziprasidone
Re-uptake Blockers
Fluoxetine, Fluvoxamine
Clovoxamine
Imipramine, Amitriptyline
Clomipramine
Desipramine
Tranylcypromine
Sertraline, Fenfluramine
OTHER
H2 Antagonists
Cimetidine, Ranitidine
Opiates
RELEASE
VIP, OT, TRH
GABA Cimetidine, Lithium
Valproate, Alprazolam
Estrogens
Estrogens, Clonazepam
VIP and OT
Figure 2 Schematic representation of mechanisms of drug-induced hyperprolactinemia.Therapeutics and Clinical Risk Management 2007:3(5) 934
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mented in women on antipsychotics, in whom the prevalence 
of symptomatic hyperprolactinemia reaches 50% or more, 
the most common symptoms being galactorrhea and men-
strual irregularities (Wieck and Haddad 2002; Halbreich et al 
2003). However, little information is available on the gen-
der-speciﬁ  c response to prolactin elevating antipsychotics. 
On equal doses, women on chronic prolactin-raising 
antypsichotic seem more likely to develop hyperprolactinemia 
than men, and they reach signiﬁ  cantly higher prolactin 
levels during the treatment (Smith et al 2002; Kinon et al 
2003a). Among male patients, age was not found to inﬂ  uence 
prolactin concentration, while in women a younger age was 
associated with higher prolactin levels, as expected for their 
reproductive status (Halbreich and Kahn 2003; Montgomery 
et al 2004).
Regarding age, data from studies performed with new 
atypical drugs in elderly patients and in youths are consistent 
with previous ﬁ  ndings in adult patients: olanzapine appears to 
be a prolactin-sparing antipsychotic medication in the elderly 
(Kinon et al 2003c), and quetiapine produced signiﬁ  cantly 
less frequent hyperprolactinemic events and lower mean 
elevation of prolactin levels than the conventional drug 
risperidone in children (Stevens et al 2005).
Classical antipsychotics
Classical antipsychotics are the most common cause of 
drug-induced hyperprolactinemia (Molitch 2005). The 
antipsychotic action of these dopamine-receptor blockers is 
based on the dopamine pathogenetic hypothesis of schizo-
phrenic disorders. These drugs act as nonselective dopamine 
receptors antagonists and interfere with all four dopamine 
pathways (Figure 2). Therapeutic effects on negative and 
positive psychotic symptoms occur through dopamine D2 
and D4 receptors binding in the mesolimbic area, while 
side effects are mediated by D2 blockade in the striatal area 
(extrapyramidal effects) and in the hypothalamic infundibular 
system (hyperprolactinemia) (Wieck and Haddad 2002).
Prolactin is reported to reach higher levels on neuroleptics 
than during most of other prolactin-raising treatments and 
seem to increase proportionally to the antipsychotic therapeutic 
efﬁ  cacy (Gruen et al 1978; Green and Brown 1988).
Although prolactin does not usually reach the levels typi-
cally associated with prolactin-secereting pituitary tumors, 
cases of huge elevation are reported, above 300 ng/ml (Rivera 
et al 1976; Pollock and McLaren 1998; Smith et al 2002).
Plasma prolactin levels have been reported to increase in 
a dose-dependent manner (Smith et al 2002; Montgomery 
et al 2004; Meltzer and Fang 1976), but even low daily 
dosages of classical antipsychotics can cause signiﬁ  cant 
elevations (Wieck and Haddad 2002).
The increase begins after a few hours and persists during 
the rest of the treatment, the total effect depending on therapy 
duration: a medium-term treatment (3–9 weeks) has been 
found to increase baseline levels up to 10-fold (Meltzer 
and Fang 1976), while during chronic treatment, partial 
tolerance may lead to prolactin normalization, though after 
long-term therapy prolactin remains above normal in most 
cases (Rivera et al 1976).
After suspension of the oral treatment, prolactin returns 
to normal range within two to three weeks, depending on the 
half-life of the drug and its metabolites and on the storage 
in the fatty tissue, but remains above pre-treatment values 
for six months after discontinuation in case of intramuscular 
depot administration (Wieck and Haddad 2002).
Butyrrophenones. Haloperidol is a butyrrophenone used 
for the treatment of schizophrenia, tics, stutter or delirium. 
Endocrinologic side effects (amenorrhea, galactorrhea, gyne-
comastia, sexual dysfunction, mastalgia) occur at undeﬁ  ned 
frequency.
A study of haloperidol (10–20 mg) versus placebo 
showed association of the treatment with prolactin elevation, 
persistent at sixth week of therapy (Crawford et al 1997). 
Substantial increases, up to nine-fold above basal levels, 
have been found after single injections of haloperidol, with 
persistent, though less consistent, elevation (three-fold) 
after weeks of treatment (Goodnick et al 2002). Prolactin 
response to haloperidol, studied in 15 patients, with prolac-
tin sampling taken every 3 days, showed a distinct pattern: 
prolactin concentration quickly increased in the ﬁ  rst 6–9 
days, reaching a peak between 30 and 50 ng/mL, and then 
a plateau that remained mainly constant throughout the 
study, always below 77 ng/mL. The pattern and amplitude 
of the increase were not inﬂ  uenced by the dose administered 
(Spitzer et al 1998).
Phenothiazines. Acute increases, of two- to tenfold, 
have also been observed after single parenteral or oral doses 
of phenothiazines. Prolactin elevation induced by a single 
ﬂ  uphenazine injection was found to last up to 28 days. 
Long term studies have documented an initial increase in 
prolactin levels (three-fold above normal range) in the ﬁ  rst 
three days of treatment, with a subsequent further increase 
(up to two-fold) during the following weeks of treatment. 
In this case, no gender-dependent response was observed 
(Goodnick et al 2002).
A great, dose-dependent increase in prolactin has been 
observed in 40% to 90% of patients treated with phenothi-Therapeutics and Clinical Risk Management 2007:3(5) 935
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azines (Rivera et al 1976; Kinon et al 2003a). Chlorproma-
zine-induced hypeprolactinemia is reported to develop earlier 
during the treatment and to reach higher levels in women 
than in men (Meltzer et al 1983). The increase begins hours 
after the ﬁ  rst i.m. or oral administration (Mannisto et al 1978; 
Busch et al 1979) and high levels persist during treatment 
period (Kolakowska et al 1976).
Thioridazine 50 mg was found to increase prolactin at 
level similar to those observed after chlorpromazine, within 
the ﬁ  rst two hours following administration (Sachar et al 
1975).
Thioxanthenes. In a study that compared the effects 
of thiothixhene and thioridazine (Crowley and Hydinger-
Macdonald 1981), prolactin levels increased equally with 
the two drugs, but another study documented exaggerated 
hyperprolactinemic response to thiothixene in one subject 
(Ash and Bouma 1981).
Unlike other “classical” thioxanthenes, ﬂ  upenthixol shows 
an “atypical” receptorial proﬁ  le, with a mixed dopamine D1/D2, 
serotonin and histamine H1 receptorial antagonism. In this 
regard, ﬂ  upentixol could be referred to as “partial atypical” 
neuroleptic (Kuhn 2000). Indeed, prolactin levels during 
prolonged therapy with ﬂ  upenthixol were found to increase 
two- to three-fold above baseline during the ﬁ  rst month of 
therapy, with reduction at month 3 and 6 and normalization 
over the next few months (Schlosser et al 2002).
Others. The effect on prolactin levels of pimozide 
administration seems to be the result of an impaired dopamine 
secretion to portal vessels, rather than the consequence of 
a reduction of hypothalamic dopamine production (Aguilar 
et al 1985).
Atypical antipsychotics
Atypical antipsychotics are characterized by increased 
antipsychotic efﬁ  cacy and fewer neurological and endocrine-
related side effects as compared to classical antipsychotic 
drugs. Most of them elicit poor hyperprolactinemic response 
or no hyperprolactinemia at all. There are several hypoth-
eses to explain the “atypical” behavior on prolactin levels: 
regional limbic selectivity (Goldstein 1999), preferential 
binding to D3 and D4 (Kuhn 2000), peculiar binding dynamics 
at the D2 receptors or differences in afﬁ  nity to D2 (Seeman 
2002), combined antagonism of dopamine and serotonin 
receptors (Kuhn 2000).
Receptor binding dynamics have been widely investigated 
and are now completely identiﬁ  ed: while classical drugs are 
complete dopamine antagonists, the newest antipsychotics 
exert a mixed dopamine-agonistic/antagonistic activity 
(Lieberman 2004). Partial agonists have a lower intrinsic 
activity at receptors than full agonists, and that allows them 
to act either as a functional antagonist or agonist depending 
on the surrounding levels of naturally neurotransmitters, that 
are fully agonists (Lieberman 2004). This results in an early 
dissociation from the receptor, that enables a normal dopa-
minergic neurotransmission in tuberoinfundibular pathway 
and avoids hyperprolactinemia (Lieberman 2004).
Most clinical studies on atypical drugs have been limited by 
blood sampling after 12 to 24 hours from the drug administra-
tion, not allowing the detection of early hyperprolactinemia. 
Indeed, clinical studies of pharmacokinetics have shown 
a transient D2 blockade by atypical antipsychotics with an 
early hyperprolactinemic effect after acute administration. 
Accordingly, only monitoring of prolactin levels within the ﬁ  rst 
24 hours after oral administration of atypical antipsychotics 
may reveal early modiﬁ  cations: prolactin serum concentration 
increases within the ﬁ  rst six hours after drug administration 
(up to two-fold from basal level) with a variable mean peak 
time, also in relation to the speciﬁ  c drug (120 min for risperi-
done, 180 min for clozapine and 290 min for olanzapine), and 
return to baseline values within 12–24 hours. More speciﬁ  cally, 
only clozapine and risperidone result in a pathologic elevation, 
while olanzapine-induced prolactin increase is always within 
normal range (Turrone et al 2002).
The hypothesis of a transient blockade of D2 receptors has 
been supported by PET scans showing that haloperidol con-
stantly binds to D2 for 24 hours, while receptors occupation 
by atypical drugs is signiﬁ  cantly shorter and mostly expired 
at the 24th hour (Seeman 2002), supporting the hypothesis 
of a transient D2 blockade.
Indeed, partial agonistic activity was observed with 
bifeprunox and aripiprazole. Other antipsychotics, such as 
olanzapine, ziprasidone and clozapine, have been associated 
with attenuated dopamine-induced ERK phosphorylation 
(Bruins et al 2006).
A second theory is that of a simultaneous binding at 
D2 and 5-HT2A receptors, leading to a more physiologic 
serotonin-dopamine balance (Seeman 2002). The effects of 
the new antipsychotics on dopamine D2/serotonin 5-HT1A 
receptors have been recently investigated: antipsychotics, with 
the exception of olanzapine, exhibited agonist properties at 
serotonin 5-HT1A receptors, the greatest E-max values being 
found for bifeprunox, efﬁ  caciously stimulating both serotonin 
5-HT1A and dopamine D2 receptors, followed by aripiprazole, 
ziprasidone and clozapine (Bruins et al 2006).
Risperidone. Risperidone is one of the atypical antipsy-
chotics most likely to induce hyperprolactinemia. This drug Therapeutics and Clinical Risk Management 2007:3(5) 936
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is used for the treatment of schizofrenia, bipolar disturb, 
acute mania, dementia, Tourette syndrome and autism. 
Risperidone has a dose-dependent serotonin and dopamine 
antagonistic action. It binds with very high afﬁ  nity to sero-
toninergic 5-HT2 receptors, in the CNS and in periphery, and 
to dopamine D2 receptors, with an afﬁ  nity 20-fold lower, but 
relatively higher compared to other atypical antipsychotics. 
Risperidone causes more marked elevations in prolactin 
than other atypical antipsychotics because it does not fully 
cross the blood-brain barrier, hence D2 receptor occupancy 
is higher at the level of the pituitary than in the striatum. 
However, the effect on prolactin levels is unlikely related 
to 5HT2 receptors binding, which would result in inhibition 
of prolactin secretion. Endocrinologic side effects, such as 
amenorrhea, galactorrhea, gynecomastia, sexual dysfunction 
in patients on risperidone are documented with a frequency 
of 1%–10%.
Current data show that, similarly to conventional anti-
psychotics, high doses of risperidone (>6 mg/day) increase 
prolactin levels to the range typically associated with sexual 
dysfunction in otherwise healthy patients (Petty 1999). Some 
studies report that risperidone would raise prolactin levels 
even more than the classic antipsychotics: comparative 
studies showed a signiﬁ  cantly higher prevalence and higher 
prolactin mean levels in risperidone-treated patients, as 
compared to patients treated with conventional (Kleinberg 
et al 1999; Kinon et al 2003a) or atypical antipsychotics such 
as clozapine (Kearns et al 2000). However, in other studies 
(Kearns et al 2000), the rise in prolactin levels was lower 
with risperidone than with classical neuroleptics. In the same 
study by Kearns et al, prolactin increase under risperidone 
was present in 12 out of 12 patients and was inﬂ  uenced by 
age and gender (but not by duration of the therapy), being 
higher in young females.
On risperidone and haloperidol therapy, prolactin serum 
concentration increases within a few hours after acute treat-
ment, and remains permanently high during an extended 
period (up to 54 weeks for risperidone and 52 for haloperidol) 
(Tollefson et al 1997; Purdon et al 2000). Cases of successful 
treatment with dopamine agonists of risperidone-induced 
hyperprolactinemia are reported (Tollin 2000).
Amisulpride. Amisulpride is a substituted benzamide 
derivative, characterized by little extrapyramidal symp-
toms (EPS) but great prolactin elevation, similar to that of 
conventional antipsychotics and often clinically relevant 
(Fric and Laux 2003). Since amisulpride is a highly selec-
tive D2/D3 receptor antagonist, its “atypical properties” 
cannot be explained by combined 5-HT2/D2 antagonism 
(Leucht et al 2002), but rather by a preferential occupancy 
of dopamine receptors in limbic than in striatal regions 
(McKeage and Plosker 2004). High dosages of amisulpride 
seem to preferentially antagonize postsynaptic D2/D3 recep-
tors, resulting in reduced dopamine transmission, while low 
dosages preferentially block presynaptic D2/D3 receptors, 
resulting in enhanced dopamine transmission (McKeage 
and Plosker 2004). To explain prolactin elevation with low 
extrapyramidal symptoms, it has recently been hypoth-
esized that amisulpride may determine a selective higher 
occupancy of D2/D3 at the pituitary level than at central 
regions, because of its poor brain barrier permeability 
(Bressan et al 2004).
Amisulpride-induced hyperprolactinemia is reported 
after both acute and chronic treatment and does not seem 
to be strongly dose-related: samples taken during the ﬁ  rst 
eight hours following 20 or 100 mg i.v. single administra-
tion in ten healthy subjects revealed a signiﬁ  cant elevation 
of prolactin levels (8–10 fold above baseline) (Wetzel 
et al 1994). Long-term amisulpride treatment was found 
to lead to a constant but slow decline in prolactin levels, 
that remained signiﬁ  cantly elevated until the 12th month of 
treatment and then signiﬁ  cantly decreased, but still above 
normal range, during the ﬁ  rst three months after suspen-
sion (Schlosser et al 2002). Therefore, amisulpride chronic 
therapy in patients treated with antidepressants or benzodi-
azepines can potentially worsen hyperprolactinemia, even 
at low doses (Kopecek et al 2004). However, the safety 
proﬁ  le of amisulpride, as reported from a comparison of 
18 clinic trials, appears to be better than traditional neuro-
leptics (Leucht et al 2002), but it is reported more likely to 
cause hyperprolactinaemia than risperidone or olanzapine, 
amenorrhoea occurring in about 4% of treated women 
(McKeage and Plosker 2004). A recent study reported the 
rapid and complete reversibility of amisulpride-induced 
prolactin elevation in 17 psychiatric patients, with signiﬁ  -
cant reduction after 14 to 51 days after discontinuation, 
independently from dosage (50–800 mg/day) or treat-
ment duration. (Paparrigopoulos et al 2006). In that study 
(Paparrigopoulos et al 2006), mean prolactin increase was 
signiﬁ  cantly greater in women than in men.
Prolactin pattern after 100 mg i.m. of the benzamide 
sulpiride, analyzed in 10 healthy patients through blood sam-
pling at 30, 60 and 120 minutes has showed a quick, marked 
and permanent increase (Mancini et al 1976).
Molindone is another atypical new drug able to cause 
sustained hyperprolactinemia. In a study by Pandurangi 
et al, prolactin showed a positive dose-effect response in Therapeutics and Clinical Risk Management 2007:3(5) 937
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14 psychiatric patients receiving high doses of molindone 
(Pandurangi et al 1989).
Problems related to hyperprolactinaemia occur less often 
with some atypical antipsychotics than with typical drugs, 
even though risperidone and amisulpride appear to have no 
advantages on this regard. Some other atypical antipsychotics, 
such as clozapine, olanzapine, quetiapine, sertindole, and 
ziprasidone cause only mild and transient hyperprolactinemia 
(Stanniland and Taylor 2000).
Clozapine. Clozapine, the prototypic atypical antipsy-
chotic drug, antagonizes serotonin and dopamine receptors. It 
has been proposed that the selective interaction of clozapine 
with dopamine D1, D2 and D4 and 5HT2 receptors results in a 
distinctive alteration in the function of pre- and post-synaptic 
dopamine elements, with the hyperprolactinemic effect being 
mediated by supra-pituitary action of the drug (Meltzer and 
Gudelsky 1992). The lack of prolactin increase following 
clozapine administration could be due to both the sparing 
of dopamine-mediated inhibition of prolactin release and 
the direct stimulatory effect on TID neurons (Meltzer and 
Gudelsky 1992). Moreover, clozapine does not interfere with 
norepinephrine-mediated inhibition of prolactin secretion 
(Lamberts et al 1990). In in vitro cultured pituitary tumor 
cells, clozapine at high concentration appeared to directly 
inhibit prolactin release and DNA content, suggesting anti-
mitotic action on the lactotrophs (Lamberts et al 1990). 
Early single-dose trials reported that clozapine reduced 
hyperprolactinemia by 16%–80% during 6 weeks of drug 
administration (Goodnick et al 2002).
Olanzapine. Olanzapine is a potent 5-HT2 blocker 
that shows higher afﬁ  nity for 5-HT2 than D2 at all doses. 
D2 occupancy is dose-dependent and seems to be similar 
to risperidone pattern, greater than clozapine. At the usual 
clinical dose range of 10–20 mg/day, receptor occupancy 
varies from 71% to 80%, a restricted range that may explain 
the modest extrapyramidal side effects and prolactin eleva-
tion. However, doses greater than 30 mg/day are associated 
with more than 80% D2 occupancy and may induce prolactin 
elevation (Kapur et al 1998). A double-blind placebo and 
haloperidol controlled trial of three doses of olanzapine, 
enabled the analysis of the temporal trend of serum pro-
lactin among 137 patients. After two weeks of treatment, 
only the groups of medium and high olanzapine dosage 
(7,5–17,5 mg/day) differed signiﬁ  cantly from the placebo 
group, with prolactin elevation being less frequent, lower in 
magnitude and duration compared to the haloperidol-treated 
group. At week 6, all olanzapine-treated groups exhibited an 
incidence of prolactin elevation comparable to that of the 
placebo group. Rates of elevation were approximately one-
third to half those observed with haloperidol and were more 
transient (Crawford et al 1997). Another large comparison 
study with haloperidol by Tollefson et al on 1996 patients 
conﬁ  rmed these data both during acute and extended treat-
ment (up to 52 weeks) (Tollefson et al 1997). Olanzapine was 
associated with a favorable safety proﬁ  le and signiﬁ  cantly 
fewer discontinuations of treatment due to adverse events 
(Tollefson et al 1997).
David et al documented signiﬁ  cantly higher prolactin lev-
els under risperidone than under olanzapine or haloperidol, 
in a side by side analysis of three independent multicenter, 
double blind randomized clinical trials, with a moderate 
increase in serum prolactin concentration for olanzapine 
(1–4 ng/ml), intermediate for haloperidol (17 ng/ml) and 
high for risperidone (45–80 ng/ml) (David et al 2000). No 
consistent dose-response relationship was observed for any 
of the drugs; the time course and sex dependency of the 
response differed among the three studies, though risperidone 
was found to be associated with early peaks and the mean 
change in prolactin was found to be greater in women treated 
with haloperidol or risperidone (David et al 2000).
In 2003, Kinon et al collected the results of ﬁ  ve clinical 
trials on the factors that could inﬂ  uence serum prolactin levels 
in antipsychotic treated subjects, such as type of treatment, 
gender, time course and age. In addition, the potential reduc-
tion or reversibility of the endocrinologic side effect was also 
studied. From the comparison of two contemporary studies 
of olanzapine vs haloperidol (Tollefson et al 1997) and of 
olanzapine vs risperidone (Tran et al 1997), prolactin levels 
raised several fold above baseline in patients treated with 
risperidone and haloperidol but not in those treated with olan-
zapine, with the highest levels observed for risperidone group 
and females. Similar treatment- and gender-dependent effects 
were observed in a study directly comparing olanzapine, 
risperidone and haloperidol (Purdon et al 2000). The switch 
patterns comparison attested the reversibility of classical 
and risperidone-induced hyperprolactinemia when previous 
drug is gradually discontinued and a prolactin-sparing drug 
is simultaneously initiated (Kinon et al 2000).
Melkersson reported the following prevalence of 
treatment-induced hyperprolactinemia in 75 patients: 
risperidone (medium daily dosage 3 mg/day) 89%, 
olanzapine (medium daily dosage 10 mg/day) 24% and 
clozapine (medium daily dosage 400 mg/day) 0%. Mean 
prolactin levels were signiﬁ  cantly higher in risperidone and 
olanzapine-treated subjects as compared to clozapine-treated 
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La Torre and Falorni
Although higher afﬁ  nity for 5-HT2 receptors than for 
D2 dopamine receptors is a common feature of atypical 
neuroleptics, considerable differences in their clinical and 
pharmacological properties are present. At clinical doses, 
atypical neuroleptics occupy serotoninergic receptors near to 
saturation, but show considerable differences on D2 receptor 
occupancies, with clozapine showing the lowest degree of 
occupation, as conﬁ  rmed by blunted prolactin responses to the 
acute administration of the dopaminergic drug haloperidol after 
olanzapine but not after clozapine administration (Markianos 
et al 2002). The fact that prolactin responses to haloperidol 
were not altered after treatment with clozapine, but were sig-
niﬁ  cantly reduced after the olanzapine treatment indicates that 
there is a difference between the two drugs in their capacity to 
block dopamine receptors at the hypothalamus-pituitary level, 
consistently with SPECT receptor binding results on striatal 
dopamine receptors (Markianos et al 2002).
Other atypical drugs. Quetiapine, aripiprazole and 
ziprasidone are reported either to cause no prolactin increase 
at all or to increase it transiently and mildly: serial blood 
samples showed a rapid raise in prolactin levels (up to 1.5- to 
2.5-fold above basal levels) during the ﬁ  rst two-four hours 
after drug administration and normalization within the fol-
lowing eight hours (Turrone et al 2002).
Quetiapine interacts with a wide range of neurotrans-
mitter receptors and has a high afﬁ  nity for serotonin 5HT2A 
receptors and lower afﬁ  nity for dopamine D2 receptors. 
Furthermore, quetiapine seems to be selective for meso-
limbic and mesocortical dopamine receptors, with relative 
sparing of TIDA system (Goldstein JM 1999). Quetiapine 
transient action on prolactin elevation corresponds to a 
transient dopamine D2 occupancy: a single administration 
leads to receptor occupancy that ranges from 58%–64% 
after two to three hours, with D2 occupancy decreasing to 
minimum (0%–27%) within 12 hours. This high, but tran-
sient, D2 occupancy, which decreases to very low levels 
by the end of the dosing interval, can explain its efﬁ  cacy 
and lack of prolactin elevation (Kapur et al 2000). This 
conclusion has been conﬁ  rmed by clinical data acquired 
from a comparison study with haloperidol, carried out in 
35 schizophrenic patients, that showed persistently and 
signiﬁ  cantly lower prolactin concentration at the 6th week 
control in the quetiapine treated group (Atmaca et al 2002). 
These data conﬁ  rm preliminary clinical studies that docu-
mented a quetiapine effect on prolactin levels not different 
from placebo at week 6 (Hamner et al 1996).
Aripiprazole, a new atypical antipsychotic, has a unique 
receptor binding proﬁ  le, resulting in a potent (ie, active at 
low dose) but “partial” agonistic effect at D2 and 5HT1A 
(Buckley 2003; Bruins et al 2006) and complete antagonistic 
effect at 5HT2A receptors (Taylor 2003; Lieberman. 2004) 
(Figure 2). In vitro partial agonism at D2 receptor coincides 
with a reduced prolactin release in vivo, as conﬁ  rmed in a 
comparison study of haloperidol vs aripiprazole oral admin-
istration (Cosi et al 2006).
Ziprasidone exerts agonistic properties at serotonin 
5-HT1A receptors (Bruins et al 2006). In one controlled study 
of ziprasidone vs haloperidol 15 mg, only transient eleva-
tions in prolactin were observed, with return to the normal 
range within the dosing interval, at every dose of ziprasidone 
administered (4–160 mg/day) (Goff 1998).
Zotepine is another drug reported to cause prolactin 
elevation during both acute and chronic administration (Von 
Bardeleben et al 1987).
Perospirone impact on serum prolactin levels was 
investigated in 41 schizophrenic patients receiving clinically 
effective doses: blood samples obtained 10–14 hours after 
perospirone administration showed median levels of prolactin 
within normal range (in both female and male patients), still 
normal after more than 4 weeks. These results suggest that in 
contrast to risperidone, where baseline prolactin levels were 
elevated 5.3-fold in female and 4.2-fold in male patients, 
baseline prolactin levels were not elevated after treatment 
with perospirone (Togo et al 2003). However, these results 
should be carefully interpreted, because drug-by-time inter-
actions are reported in antipsychotic-induced hyperprolac-
tinemia (Togo et al 2003).
In summary, effects of antypsychotic medications on serum 
prolactin seem to be multifactorial. It seems that both drug 
type and gender inﬂ  uence the risk for developing hyperpro-
lactinemia, with women being more sensitive than males and 
risperidone and typic drugs more likely to induce hyperpro-
lactinemia than olanzapine (Kinon et al 2003b). The elderly 
age seemed to inﬂ  uence the prolactin response, leading to a 
blunted reaction to conventional antipsychotics (Street et al 
2000) when compared with the subjects of the study by Purdon 
et al 2000, aged 28.87 ± 8.36, as reported by Kinon et al 2003b. 
Among antypsychotic, classical drugs, and more speciﬁ  cally 
haloperidol, chlorpromazine, thioridazine and thiothixene, 
induce sustained hyperprolactinemia. Atypical drugs show a 
better pharmacological proﬁ  le under this respect, even though 
risperidone, amisulpride and zotepine induce hyperprolactine-
mia with frequencies and levels similar to those observed 
with classical drugs. Other atypical drugs, such olanzapine, 
clozapine or aripiprazole can be used in switching protocols 
to correct an antipsychotic-induced hyperprolactinemia.Therapeutics and Clinical Risk Management 2007:3(5) 939
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Management of antipsychotic-induced hyperprolactinemia
The importance of monitoring for health problems, among 
which amenorrhea, in patients on psychotropic treatment, 
has been stressed during an expert consensus on the pharma-
cologic treatment of psychotic disorders (Kane et al 2003). 
For their peculiar activity on dopamine receptors, atypical 
antipsychotics are usually associated with a broader spectrum 
of clinical efﬁ  cacy and are better tolerated as compared to 
conventional agents. However, adverse effects such as weight 
gain and metabolic changes are cause for concern, even in 
patients treated with some of the newest drugs (Cassano 
et al 2007). The management of antipsychotic-induced 
hyperprolactinemia should include subsequent measures, in 
order to minimize the side effects, thus optimizing therapy 
compliance and reducing the risk of subsequent psychotic 
relapses. Avoiding hyperprolactinemia and its long-term 
complication means improving treatment outcomes and 
enhancement of quality of life.
A safe and effective approach to drug-induced hyperpro-
lactinemia should consist in prolactin measurement in symp-
tomatic patients on antipsychotic treatment and, routinely, 
in all the patients taking conventional drugs or risperidone 
(Miller 2004). Patients showing plasma prolactin levels 
100 ng/ml should undergo hypophiseal NMR to rule out 
the presence of a prolactinoma. In case of hyperprolactinemia 
during antipsychotic treatment, once other potential causes 
have been excluded, prolactin normalizing strategies should 
be attempted when clinically signiﬁ  cant hyperprolactinemia 
occurs, speciﬁ  cally amenorrhea in women or testosterone 
deﬁ  ciency in men (Haddad and Wieck 2004; Miller 2004).
Traditional pharmacological approach of hyperprolac-
tinemia in schizophrenic patients can raise some problems, 
even when no concomitant antipsychotic treatment is present, 
because of the potential worsening effect of dopaminergic 
drugs on psychosis. The hypothesis that the pathophysiology 
of negative symptoms in schizophrenia may involve relative 
hypoactivity of central dopaminergic neurotransmission, 
however, led to the exploration of dopamine agonist strate-
gies in the treatment of this condition (Levi-Minzi et al 1991). 
Although the use of dopamine agonists in otherwise unmedi-
cated schizophrenic patients often leads to the exacerbation 
of psychosis, trials of dopamine agonists in combination 
with neuroleptic agents warrant investigation (Levi-Minzi 
et al 1991).
The effects of bromocriptine (5.0–7.5 mg/day) on 
antipsychotic-induced prolactin-related endocrinological 
disturbances (amenorrhea, galactorrhea and impotence) 
were investigated in psychiatric patients receiving classical 
neuroleptics (Matsuoka et al 1986), with the following 
results: menstrual cycles recurred in 7 of 10 patients with 
amenorrhea, a decrease in lactation appeared in 5 of 6 patients 
with galactorrhea and a signiﬁ  cant increase in the serum 
levels of testosterone was observed after 8 weeks of treatment 
in six out of six male patients. In the same study (Matsuoka 
et al 1986), no remarkable deterioration of psychotic symp-
toms was reported in 6 schizophrenic patients. In another 
study (Smith 1992), one woman out of 6 developed worsened 
psychiatric symptoms while taking bromocriptine (daily dos-
age 5–10 mg) and had to discontinue the therapy.
Concerning atypical drugs, the optimal management of 
risperidone-induced hyperprolactinemia has not been clari-
ﬁ  ed, though it is widely assessed that risperidone can cause 
clinically signiﬁ  cant hyperprolactinemia. Tollin (Tollin 
2000) reported 4 patients on risperidone, with signiﬁ  cant 
hyperprolactinemia (65.5 to 209 ng/ml) that showed reduc-
tion of prolactin level and alleviated hypogonadism after 
dopamine agonists (bromocriptine or cabergoline) were 
added, without deterioration of psychotic symptoms. 
A more recent pilot study (Cavallaro et al 2004) attested 
the safety and efﬁ  cacy of a low dose cabergoline (0.125 to 
0.250 mg/week) administered for 8 weeks in 19 male and 
female schizophrenic patients with risperidone-induded 
symptomatic hyperprolactinemia. Mean plasma prolactin 
levels, assessed at baseline and at the end of the study, 
were signiﬁ  cantly decreased in all the patients, and within 
the normal range in 11 patients, with remission of clinical 
signs; in this study no side effects or changes in the patients’ 
psychopathology were observed.
Cases of successful treatment of risperidone-induced 
hyperprolactinemia with cabergoline in youths are also 
reported (Cohen and Biederman 2001): the addition of 
cabergoline (initial mean dose 2.13 +/– 0.09 mg/week) in four 
male children on risperidone with plasma prolactin ranging 
57.5–129 ng/ml, led to serum prolactin levels normalization. 
Cabergoline was well tolerated without adverse effects during 
the whole treatment (13–21 months) on maintenance dose 
of 1 mg/week.
A case report has been reported of bromocriptine efﬁ  cacy 
in resolving amisulpride-induced hyperprolactinemia 
(Bliesener et al 2004).
Although dopamine-agonists have successfully been used 
in patients with antipsychotic–induced hyperprolactinemia, 
bromocriptine treatment is reported to be associated with 
exacerbation of acute psychotic state in psychotic women 
(Frye et al 1982; Dorevitch et al 1991). Discontinuation of the 
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resulted in complete remission. Caution is advisable in the 
use of bromocriptine especially in patients with a pre-exist-
ing psychiatric history and monitoring for changes in mental 
status when bromocriptine is prescribed is recommended. 
(Dorevitch et al 1991).
In conclusion, dopamine agonist therapy is not generally 
advisable (Miller 2004), even though successful cases are 
reported of risperidone-induced hyperprolactinemia treated 
with the addition of either cabergoline or bromocriptine, 
without worsening psychotic symptoms (Tollin 2000). 
More speciﬁ  cally, bromocriptine, conﬁ  rmed to be effective 
in reducing hyperprolactinemia and resolving amenor-
rhea/oligomennorrhea in schizophrenic women, should be 
cautiously condidered as a drug potentially exacerbating 
acute psychosis (Smith 1992), thus leading to the conclu-
sion that other treatment approaches should be suggested 
for neuroleptic-induced hyperprolactinemia and associated 
manifestations (Frye et al 1982).
Since the discontinuation of a neuroleptic therapy, or the 
addition of dopamine-agonists, may worsen the psychosis, 
and the reduction of the neuroleptic dose may not necessarily 
lead to decrease in prolactin, switching to prolactin sparing 
agents acquires great relevance.
Kinon et al (2000) studied the reversibility of hyper-
prolactinemia by comparing four medication switching 
paradigms from classical drugs or risperidone to olanzapine 
and showed the return of prolactin within normal limit three 
weeks after switching. The switch patterns comparison 
attested that reversibility of classical and risperidone-induced 
hyperprolactinemia is successful when a gradual antipsy-
chotic drug discontinuation is combined with olanzapine 
initiation (Kinon et al 2000). These results were conﬁ  rmed 
a few years later, with olanzapine found to be able to reverse 
hyperprolactinemia in conventional or risperidone-treated 
female schizophrenic patients, to decrease amenorrhea, to 
improve cycle regularity and to reduce sexual side effects, 
thus creating a safe and effective alternative method for 
patients with antipsychotic-induced hyperprolactinemia (Kim 
et al 2002; Kinon et al 2006). In this study by Kinon et al 
2006, male patients who switched to olanzapine treatment 
experienced signiﬁ  cantly (p = .03) increased free testosterone 
levels, even with no signiﬁ  cant improvement in total testo-
sterone levels; some female patients experienced improved 
menstrual cycling, as well as resolution of galactorrhea and 
gynecomastia, and sexual functioning was signiﬁ  cantly 
improved in both genders. Patients switching to olanzapine, 
as well as those remaining on their pre-study medication, 
maintained clinical stability, their symptoms continued to 
improve, although there were no signiﬁ  cant between-treatment 
differences in improvement. Treatment-emergent adverse 
events occurred in both treatment groups, with no signiﬁ  cant 
differences between groups.
A case report conﬁ  rmed the successful strategy of switch-
ing to olanzapine while tapering risperidone: one month of 
titrated dose (15 mg) olanzapine normalized serum prolactin, 
restored menstrual regularity, resolved galactorrhea and 
improved the psychiatric condition (Canuso et al 1998).
Six months olanzapine was reported effective in reducing 
prolactin levels from 116 ng/ml to 72 ng/ml also in a woman 
receiving phenothiazines. This patient recovered from 
galactorrhea and menstrual irregularities and her psychiatric 
condition remained stable (Canuso et al 1998).
Bunker et al reported a case of correction of serum 
prolactin levels after conversion to clozapine therapy in a 
16-year-old female patient who had developed hyperprol-
actinemia with galactorrhea and amenorrhea while receiving 
thioridazine 300 mg daily and after a period of treatment with 
bromocriptine (Bunker et al 1997).
Successful management of antipsychotic-induced 
hyperprolactinemia with switching to quetiapine has also 
been reported (Keller and Mongini 2002; Kunwar and 
Megna 2003).
Aripiprazole provides to clinicians another treatment 
option, both as a ﬁ  rst-line antipsychotic agent and a switch-
ing possibility from maintenance therapy, as conﬁ  rmed by 
the report of an expert consensus meeting of October 2005 
that aimed to agree on a set of guidelines for best-practice 
use of aripiprazole in the acute and long-term management 
of schizophrenia in Italy (Cassano et al 2007). A recent pilot 
study reported the successful replacement of amisulpride and 
risperidone with aripiprazole, with normalization of prolactin 
concentration at the end of week 4 (Lee et al 2006).
Given that it may be advantageous to avoid the use of 
direct dopaminergic agents in psychotic patients, for the risk 
of worsening psychosis, it is still unclear whether this risk 
is lower when using a partial agonist agent as aripiprazole 
in combination with a full antagonist (.Cassano et al 2007). 
Indeed, because of the coexistence of high dopamine receptor 
afﬁ  nity and partial agonist properties, aripiprazole may act as 
a dopamine agonist and may restore tonic inhibition to ante-
rior pituitary lactotrophs and correct dopamine hypoactivity 
induced by risperidone (Whal and Ostroff 2005).
A single case of aripiprazole used in combination with 
another antipsychotic (risperidone) for the treatment of 
symptomatic hyperprolactinemia was reported by Wahl 
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with schizophrenia, treated with risperidone long acting 
formulation (25 mg i.m. every 2 weeks), introduction of 
aripiprazole (15 mg/day) determined a gradual resolution 
of bilateral breast pain, swelling, and galactorrhea and nor-
malization of serum prolactin from 119 ng/ml to 18 ng/ml 
(Whal and Ostroff 2005). However, the safety and efﬁ  cacy of 
the combined use of aripiprazole with other antipsychotics, 
for the treatment of drug-induced hyperprolactinemia, need 
to be demonstrated in large, controlled trials (Cassano et al 
2007).
In conclusion, a systematic evaluation of atypical neu-
roleptics as an alternative treatment for conventional drug-
induced hypeprolactinemia is recommended. Switching to 
olanzapine has been proven to be an advantageous treatment 
of hyperprolactinemia in women with schizophrenia (Kinon 
et al 2000, 2006; Kim et al 2002). Also clozapine (Bunker 
et al 1997), quetiapine (Kunwar and Megna 2003) and 
aripiprazole (Lee et al 2006; Cassano et al 2007) seem to be 
reasonable substitutive treatment options for patients suffer-
ing from old neuroleptic- and risperidone-induced hyperprol-
actinemia. As for the use of aripiprazole in combination with 
other antipsychotics, large clinical trials are needed.
Antidepressant drugs
Only a few data concerning the effect of antidepressant drugs 
on prolactin secretion are currently available. Unlike neuro-
leptics, the action of antidepressant drugs on the neuroendo-
crine system is highly variable and not strictly related to their 
therapeutic efﬁ  cacy (Meltzer et al 1982). This heterogeneity 
reﬂ  ects the complexity of the aminergic control on pituitary 
hormone secretion and the role of antidepressants on these 
pathways (Goyot et al 1985). Antidepressant drugs with 
serotoninergic activity, including selective serotonin reuptake 
inhibitors (SSRI), monoamine oxidase inhibitors (MAO-I) and 
some tricyclics, can cause modest and generally asymptomatic 
hyperprolactinemia (Wieck and Haddad 2003; Molitch 2005) 
(Table 2 and Figure 2). Monotherapy-treated patients rarely 
reported symptoms due to increased prolactin secretion, while 
in patients on antipsychotic drugs that stimulate prolactin 
secretion, serotoninergic antidepressants may elevate prolactin 
levels above symptomatic levels or worsen pre-existing symp-
toms (Haddad and Wieck 2000). Most serotonin reuptake 
inhibitors can slightly elevate prolactin, with the exception of 
sertraline (Foley and Kast 2006). The atypical (ie, alone in their 
class) antidepressants mirtazapine and bupropion, are prolac-
tin neutral (Foley and Kast 2006) the latter being previously 
reported to even decrease serum prolactin, maybe through a 
dopamine re-uptake blockade (Meltzer et al 1982).
Heterocyclic antidepressants. Heterocyclic antidepres-
sants are reported to induce only mild hyperprolactinemia, 
but further studies are needed. Some of them, such as the 
tertiary amines imipramine (Nutt et al 1987), amitriptyline 
(Schlienger et al 1980) and clomipramine (Anderson and 
Cowen 1986) and the secondary amine desipramine (Price 
et al 1989), are thought to share a serotoninergic mechanism 
with SSRI.
A study on 14 patients on the tertiary amine amitriptyline 
showed an increase of 100% above pre-treatment prolactin 
level in 14% of the patients (Meltzer et al 1982), while 
a moderate (about 25%), though statistically signiﬁ  cant, 
increase in plasma prolactin was reported in 17 patients 
daily treated with the secondary amine nortriptyline for three 
weeks, even though it was never above the symptomatic 
threshold (Nielsen 1980).
Prolactin levels, evaluated in depressive patients after 
acute and chronic administration of tricyclic antidepressants 
clomipramine and amitriptyline, were found to temporary 
rise during the ﬁ  rst day of treatment in 6 patients out of 11, 
with a delay in relation to the drug plasma peak. After 28 
days of therapy, a signiﬁ  cant increase was observed in the 
clomipramine-treated group and a signiﬁ  cant decrease in the 
amitriptyline group (Goyot et al 1985).
The abolishment of prolactin response to clomipramine 
after pre-treatment with serotonin receptor blockers clozapine 
and olanzapine (Markianos et al 2002) and its enhancement 
after L-tryptophan (Anderson and Cowen 1986) conﬁ  rm the 
involvement of serotoninergic pathway in clomipramine-
induced prolactin increase. Therapeutic doses of clomip-
ramine had been associated with non-puerperal lactation 
and elevated plasma prolactin, both disturbances recovering 
within weeks after drug discontinuation (Fowlie and Burton 
1987). Treatment with either clomipramine or maprotiline 
in 17 patients with major depressive disorder and in healthy 
subjects increased signiﬁ  cantly basal prolactin levels, that 
were also signiﬁ  cantly higher in responders than in non-
responders. This increase is possibly the result of a weak 
inhibition of prolactin secretion, due to down-regulation 
of beta-adrenergic receptors, and/or enhanced activity of 
prolactin stimulating serotoninergic receptors (Baumgartner 
et al 1988). However, Schlienger et al showed that basal plas-
ma levels of prolactin and delta prolactin response to TRH 
were increased in women on clomipramine but remained 
normal under maprotiline, in agreement with the different 
pharmacologic effect of these two classes of drugs, tricyclics 
mainly inhibiting serotonin, while tetracyclics rather norepi-
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No evidence for a hyperprolactinemic effect of mianserine 
is reported (Meltzer et al 1982).
Desipramine administration was found not to affect 
prolactin levels in 24 patients on short term treatment (one 
week), but signiﬁ  cantly enhanced prolactin levels after four 
weeks (Price et al 1989).
The effect of traditional tricyclic antidepressant imipramine 
on serum prolactin levels is controversial: oral administra-
tion of 100 mg, but not of 40 mg, led to consistent rise in 
prolactin levels, as measured in nine healthy young men, the 
effect being the result of serotonin enhancement following 
reuptake inhibition (Nutt et al 1987). A previous ﬁ  ve-week 
double-blind study on depressed patients did not show any 
signiﬁ  cant change in serum prolactin levels after imipramine 
therapy (Cooper et al 1981). The lack of prolactin raising 
effect and of antipsychotic properties is possibly explained 
with imipramine and other traditional tricyclic antidepressants 
not affecting dopamine transmission (Cooper et al 1981).
Amoxapine. Amoxapine is an antidepressant known 
to have neuroleptic properties. Its in vitro proﬁ  le receptor 
occupancy pattern and preclinical effects are very similar to 
atypical antipsychotics, and it has also shown antipsychotic 
efﬁ  cacy in clinical trials (Antor et al 1983; Apiquian et al 
2005). In agreement with such properties, amoxapine was 
found to increase serum prolactin in 10 major depressed men 
signiﬁ  cantly more than the secondary amine desipramine in 
the control group (Antor et al 1983). However a random-
ized, double-blind 6-week trial performed by Apiquian et al 
in 2005 to compare the antipsychotic and side effect proﬁ  le 
of amoxapine (up to 250 mg/day) and risperidone (up to 
5 mg/day) in 39 schizophrenic patients, showed that amoxa-
pine was associated with less extrapyramidal effects and 
lower prolactin elevation than risperidone (Apiquian et al 
2005). This prolactin raising effect, that amoxapine shares 
with loxapine, a related compound widely used as neuroleptic 
(Robertson et al 1982), is reported in both female and male 
patients and may be explained with the blockade of dopamine 
receptors in central tuberoinfundibular pathways (Cooper 
et al 1981) or in the anterior pituitary gland (Robertson et al 
1982) (Figure 2).
Monoamine-oxidase inhibitors. The precise mechanism 
underlying monoamine-oxidase inhibitors (MAO-I)-induced 
hyperprolactinemia is still unknown. These drugs interact 
with several possible stimulatory pathways (Meltzer et al 
1982; Price et al 1985).
Tranylcypromine was proved to enhance prolactin 
production after administration of the serotonin precursor 
tryptophan, thus conﬁ  rming its role in serotonin function. 
The study by Price et al (Price et al 1985) showed little 
increase in prolactin concentration (3 ng/ml) after 2 weeks of 
tranylcypromine 10–40 mg/day treatment (Price et al 1985). 
Instead, hyperprolactinemia was certainly documented for 
old drugs currently not in use, such as pargyline and clor-
gyline, which acted through unknown mechanisms (Slater 
et al 1977), a hypothesis being the production of a prolactin 
releasing factor (Meltzer et al 1982).
SSRI. The development of SSRI as antidepressant drugs 
derived from the “serotonin hypothesis” of depression. These 
drugs have the ability to enhance serotonin activity, by inhi-
bition of CNS neuron serotonin reuptake. Although several 
SSRI interact with other neurotransmitters (for example ser-
traline with dopamine and paroxetine with norepinephrine), 
prolactin stimulation probably involves only serotoninergic 
pathways, since hyperprolactinemia is a constant class-
related effect, regardless of other pharmacological interac-
tions (rev. by Emiliano and Fudge 2004).
SSRI were reported to be the most frequent cause of 
drug-induced hyperprolactinemia (Cohen and Davies 1998), 
but other data do not conﬁ  rm this conclusion. SSRI actually 
cause little, if any, increase in prolactin secretion. Several 
uncontrolled studies assessed prolactin rise during SSRI 
treatment, though only paroxetine-treated patients exhib-
ited statistically signiﬁ  cant elevations, while all subjects on 
ﬂ  uoxetine, sertraline or venlafaxine showed not signiﬁ  cant 
elevations of basal prolactin (Urban and Veldhuis 1991; 
Spigset and Mjorndal 1997; Cowen and Sargent 1997).
Thirteen case reports were collected to revise the effect of 
chronic serotonin stimulation on prolactin in female patients 
on chronic SSRI therapy: prolactin raised between 28 and 
60 ng/ml in all the patients, with most of them developing 
galactorrhea, associated with amenorrhea, soon after initia-
tion of the therapy. In all the reports, hyperprolactinemia 
promptly subsided after discontinuation of the drug (Emiliano 
and Fudge 2004).
Sertraline, used for depressive illness, is the strongest 
dopamine reuptake blocker among SSRIs. Although one 
study of 15 female patients on 42.5 mg/day sertraline reported 
no difference in prolactin concentration, as compared to 
16 control subjects, evaluated up to 24 weeks of treatment 
(Šsagud 2002), a large French review on the pharmacologi-
cal causes of hyperprolactinemia, conducted on 159 patients, 
reported 27 cases (17%) due to SSRI administration (Petit 
et al 2003) with the highest incidence of SSRI-associated 
hyperprolactinemia for sertraline, followed by ﬂ  uoxetine, 
paroxetine, and ﬂ  uvoxamine. In the same study (Petit et al 
2003) only citalopram was not linked to a signiﬁ  cant increase Therapeutics and Clinical Risk Management 2007:3(5) 943
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in prolactin levels (Petit et al 2003), differently from previous 
ﬁ  ndings of an increase by 40% from basal prolactin level 
after 10 days of treatment (Laine et al 1997).
Fluoxetine is indicated in major depression and panic 
disorders with agoraphobia, ossessive-compulsive disorders, 
binge eating, bulimia, premenstrual syndrome. Fluoxetine 
clinical efﬁ  cacy is due to enhanced serotonin pathway mainly 
via postsynaptic mechanisms, with minimal effect on dopa-
mine reuptake. Fluoxetine induces a 5HT receptor–mediated 
stimulation of prolactin secretion and is reported to increase 
prolactin levels more than tricyclics (Meltzer et al 1997). The 
most common endocrinologic side effects associated with 
ﬂ  uoxetine are reduced libido (1%–11%) impaired ejacula-
tion (<1%–7%) and impotence (<1%–7%). Since ﬂ  uoxetine 
half-life varies upon duration of the treatment (1–3 days after 
short term intake, 4–6 days after chronic treatment) and its 
metabolite norﬂ  uoxetine washout is complete only after 4–16 
days, the resolution of symptoms after discontinuation may 
be slow. Frequent blood sampling after 60 mg ﬂ  uoxetine 
administered daily for 6 days to 7 female patients showed 
a signiﬁ  cant increase of mean 24-hour serum prolactin 
concentrations (16% above basal level), due to an increase 
in maximal serum prolactin peak height, without alteration 
of prolactin pulse circadian frequency (Urban and Veldhuis 
1991).
Paroxetine is used for depression, panic disorder with 
agoraphobia, obsessive-compulsive disorder, binge eating. 
The most frequent endocrinologic side effects are impaired 
libido (6%–15%), anorgasmia (2%–9%) and dismenorrhea 
(5%). In a study by Cowen and Sargent on 11 healthy subjects 
treated with paroxetine 20 mg/daily, prolactin levels showed 
no increase above pre-treatment values within the ﬁ  rst week, 
but a slight increase (by 35%) was observed at the 3rd week, 
not correlated with an increased drug plasma concentration 
(Cowen and Sargent, 1997). These data have been conﬁ  rmed 
by another study that reported signiﬁ  cant hyperprolactine-
mia in female patients treated with paroxetine for at least 
2 months (Amsterdam et al 1997). These clinical results 
support experimental data suggesting that SSRI produce a 
delayed increase in brain serotoninergic neurotransmission 
(Cowen and Sargent 1997; Porter et al 1999).
In the same study by Amsterdam et al, venlafaxine-treated 
patients showed no increase in prolactin concentration after 
two months (Amsterdam et al 1997).
Concerning ﬂ  uvoxamine, mild hyperprolactinemia was 
reported in 30 depressed patients after both short (one week) 
and long term (four weeks) treatment (Price et al 1989) and 
in two out of eight healthy subjects treated with increasing 
dosage up to 200 mg/day for 4 weeks (Spigset and Mjorndal 
1997).
Unlike other antidepressants, mirtazapine does not inhibit 
the reuptake of serotonin or norepinephrine but acts as an 
antagonist at presynaptic and, presumably, postsynaptic alpha 
2-receptors as well as an antagonist of postsynaptic 5-HT2 
and 5-HT3-receptors. Prolactin levels, measured before and 
after administration of mirtazapine i.v. did not show any 
signiﬁ  cant difference from placebo (Laakmann et al 1999). 
Schule found signiﬁ  cant lowering in plasma prolactin fol-
lowing acute oral administration of 15 mg mirtazapine in 
12 healthy male subjects, as compared to placebo (Schule 
et al 2002).
Trazodone administration was found to increase signiﬁ  -
cantly prolactin concentrations, when measured at baseline 
and after 12 hours, 1 week and 2 weeks treatment, the 
means ± S.D. of plasma prolactin concentrations increasing 
from 9.1 ± 5.6 ng/ml to a maximum of 15.3 +/– 8.5 ng/ml 
at one week (Otani et al 1995). These recent results are 
at variance with those of older studies that documented a 
decrease in prolactin concentration in ten healthy patients 
treated with trazodone (Rolandi et al 1981).
In summary, controversial data are available on antide-
pressant-induced hyperprolactinemia. Sustained and symp-
tomatic hyperprolactinemia has been demonstrated with 
the heterocyclic antidepressants amitriptyline, desipramine, 
clomipramine and amoxapine. However, SSRI have been 
reported to be the most frequent cause of drug-induced 
hyperprolactinemia. Among those, sertraline appears to be 
the most frequent cause of sustained hyperprolactinemia, but 
also ﬂ  uoxetine and paroxetine may induce pathologic and 
symptomatic increases in prolactin levels. Most of the other 
anti-depressants do not induce hyperprolactinemia or induce 
only transient or within normal range variations with no or 
little clinical relevance.
Other psychotropic drugs
Other psychotropic drugs such as lithium, valproic acid, 
buspirone, carbamazepine, and benzodiazepines rarely pro-
duce clinically relevant increases in prolactin concentrations 
(Marken et al 1992).
Buspirone is an anxiolytic drug with mixed dopamine 
agonist-antagonist and 5-HT1A agonist properties. 
Hyperprolactinemia after acute buspirone administration is 
reported in both depressive and healthy subjects, responses 
being signiﬁ  cantly higher in women than in men (Meltzer 
and Maes 1994). Prolactin levels raised in a dose-dependent 
manner (up to 320% of basal value) after administration Therapeutics and Clinical Risk Management 2007:3(5) 944
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of a dose of buspirone higher than that required for the 
anxiolytic effect (100 mg) (Seppala et al 1987). However, it 
has not been entirely clariﬁ  ed whether the serotoninergic or 
the dopaminergic system is especially accountable for the 
buspirone-induced prolactin secretive response (Maskall 
et al 1995) (Figure 2).
No published reports have so far documented hyperpro-
lactinemia as a side effect of carbamazepine treatment. In 
a study by Bonuccelli et al (1985), on normal and epileptic 
subjects, no appreciable change in prolactin spontaneous 
secretion or in prolactin secretory circadian rhythm was 
observed, though a small increase in early sleep values was 
reported. These results were interpreted to indicate that 
prolactin changes induced by carbamazepine are mediated 
by serotoninergic activity.
Clonazepam (a central type benzodiazepine agonist) and 
diazepam (a mixed agonist) are reported to decrease prol-
actin levels, possibly through a direct action on the anterior 
pituitary gland (Jarvinen et al 1992) (Figure 2).
Prolactin levels are differentially inﬂ  uenced by GABA-
ergic drugs, depending on their potency (ie, receptor afﬁ  nity) 
and dose. The robust increase in prolactin levels found in 
response to the GABA agonist alprazolam is not consist-
ent with previous data on traditional benzodiazepines: 
Zemishlany et al reported that plasma prolactin levels in-
creased by 100% two to eight hours after a single dose (3 
mg) of alprazolam (Zemishlany et al 1990).
Short-term GABA-mimetic valproate treatment in eight 
healthy male volunteers was found not to alter hypothalamic 
or pituitary 5-HT1A or dopamine receptor function (Delva 
et al 2002). In 1985, during studies on tuberoinfundibular-
GABA (TI-GABA) system, 800 mg oral valproate was found 
to decrease prolactin concentrations in 20 healthy women, 
the lack of effect in schizophrenic patients supporting the 
hypothesis of a defect of the TI-GABA system in chronic 
schizophrenia (Monteleone et al 1985).
The effects of lithium on prolactin secretion are contro-
versial. It had initially been proposed that lithium would 
increase prolactin, possibly through a decrease in dopamine 
receptor sensitivity (Meltzer et al 1982). A recent study 
showed that lithium affects variably prolactin secretion, 
in relation to duration of the therapy: a treatment of less 
than six months was found to increase prolactin levels as 
compared to controls, while bipolar patients on long term 
treatments (>six months) showed a decrease in prolactin 
levels (Basturk et al 2001). Studies that reported that lithium 
enhances signiﬁ  cantly the hyperprolactinemic response after 
clomipramine but not after metoclopramide or haloperidol 
administration indicate that the lithium-mediated prolactin 
release may selectively involve serotoninergic pathways 
(Mc Cance et al 1989). However, lithium-prolactin interac-
tions are probably even more complex and involve both 
dopamine and serotonin pathways (Basturk et al 2001).
Prokinetics
Two prokinetic drugs, that are commonly used in gas-
trointestinal disorders, induce hyperprolactinemia via a 
dopamine-antagonistic mechanism (Figure 2): metoclo-
pramide, that blocks dopamine and, at higher doses, also 
serotonin receptors in chemoreceptor trigger zone of CNS, 
and domperidone, that does not cross the blood brain bar-
rier and is therefore a selective peripheral (extra cerebral) 
dopamine antagonist. These drugs have been reported to 
cause symptomatic hyperprolactinemia (Tamagna et al 
1979; Fujino et al 1980).
Metoclopramide, a prokinetic drug used in nausea, vom-
iting, diabetic gastric stasis and gastroesophageal reﬂ  ux, 
is a potent stimulator of prolactin release. Endocrine and 
metabolic side effects, such as amenorrhea, galactorrhea, 
gynecomastia and impotence are reported with undeﬁ  ned 
frequency. Serum prolactin concentration measured soon 
after metoclopramide administration was found acutely 
increased in ﬁ  ve patients (Tamagna et al 1979). It has been 
reported that prolactin concentration may acutely increase 
up to six-fold over baseline after a single oral administration 
of 10 mg metoclopramide (Mc Callum et al 1976) and return 
to normal range after 12 hours. In these and other studies 
(Mc Callum et al 1976; Tamagna et al 1979; Browers et al 
1980) mean serum prolactin concentration was conﬁ  rmed to 
persist signiﬁ  cantly high during oral chronic treatment, up 
to 15-fold above baseline.
Domperidone is used for gastrointestinal motility dis-
orders and for the prevention of gastrointestinal symptoms 
associated with dopaminergic treatment of Parkinson’s dis-
ease. Endocrinologic side effects are reported in less than 1% 
of domperidone-treated subjects and include galactorrhea, 
gynecomastia and menstrual irregularities. Domperidone 
10 mg i.v. induced acute increase in prolactin concentration 
in healthy subjects (Sowers et al 1982), the increase occur-
ring within the ﬁ  rst 15 minutes after administration and being 
higher in women than in men (Fujino et al 1980). In contrast 
to metoclopramide, however, under chronic administration of 
domperidone, prolactin tends to decrease signiﬁ  cantly, even 
if still above the normal range (Browers et al 1980). This 
observation is consistent with the pharmacodynamic differ-
ences showed by these two drugs, as mentioned above.Therapeutics and Clinical Risk Management 2007:3(5) 945
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The effect on prolactin levels of the classical antypsichotic 
chlorpromazine, used in clinical practice for its anti-nausea 
properties, has been discussed above.
Anti-hypertensive drugs
Alpha-methyldopa is an alpha-adrenergic inhibitor, which 
is likely to decrease dopamine synthesis acting as a false 
neurotransmitter and inhibits the enzymatic conversion of 
L-dopa to dopamine catalyzed by aromatic-L-aminoacid 
decarboxylase (Steiner 1976). The most common endocri-
nologic side effect reported is gynecomastia (<1%). A single 
dose of 750–1000 mg of alpha-methyldopa is reported to 
signiﬁ  cantly increase prolactin, with a peak concentration 
occurring 4–6 hours after administration; long term treat-
ment has been associated with three- to four-fold increases 
in basal prolactin levels compared to normal subjects 
(Steiner et al 1976).
The central monoamine reserpine, used in hypertension 
but also in psychosis, schizophrenia and tardive dyskinesia, 
acts by depletion of sympathetic biogenic amines (among 
which dopamine) inhibiting their hypothalamic storage 
in secretory granules (Lee et al 1976) (Figure 2). The 
occurrence of gynecomastia is reported in patients treated 
with reserpine, with undeﬁ  ned frequency. Serum prolactin 
levels are signiﬁ  cantly higher among hypertensive patients 
receiving reserpine, compared to those found six weeks 
after discontinuation of the treatment; prolactin elevation is 
proportional to the duration of the use. Increased incidence 
of breast cancer has also been reported among patients on 
antihypertensive therapy reserpine (Lee et al 1976).
The antiarrhythmic agent class IV verapamil is a calcium 
channel blocker, indicated for the treatment of hypertension, 
angina, arrhythmias and is reported to induce galactorrhea 
in <1% of patients. In this case, the mechanism sustaining 
hyperprolactinemia is not clear, a hypothesis being a reduc-
tion in hypothalamic dopamine generation, possibly through 
N-type calcium channels (Kelley et al 1996). However, no 
other calcium-antagonist, such as diltiazem (Veldhuis et al 
1985) or dihydropiridine (Kelley et al 1996) has ever been 
associated with prolactin increase. A study published in 
1996 on 449 men receiving verapamil showed signiﬁ  cantly 
higher prevalence of hyperprolactinemia in the treated group 
than in the control group (8.5% vs 3%); serum prolactin 
levels returned to normal in all patients that discontinued 
the therapy, while 93.3% of patients still on verapamil had 
persistent hyperprolactinemia, thus conﬁ  rming the causal 
role of verapamil treatment in the development of hyperp-
rolactinemia (Romeo et al 1996).
The antihypertensive beta-blocker labetalol has been 
described to increase prolactin levels when administered 
intravenously in hypertensive patients, but not when admin-
istered orally (100 or 200 mg). This effect seems to be related 
to a central action, because pre-treatment with L-DOPA and 
carbiDOPA, reported to blunt the prolactin responses to cen-
tral stimuli, avoids prolactin response (Barbieri et al 1982).
Opiates
Consistently with the large body of evidence that endogenous 
opioid peptides participate in the regulation of pituitary secre-
tion, though with unfocused physiological roles, morphine 
and related drugs have been found to exert endocrine effects 
through interactions with dopaminergic and serotoninergic 
hypothalamic pathways and consequent modulation of pitu-
itary hormone secretion (Van Vugt and Meites 1980).
Studies on both animals and humans demonstrated that 
endogenous opioids administered either intravenously or 
intraventricularly led to a rapid and dose-dependent plasma 
prolactin increase (Van Vugt and Meites 1980; Risch et al 
1982). Opioids may indirectly stimulate prolactin release 
by inhibiting PIFs (ie, dopamine) release and/or by stimu-
lating PRFs production (Shin et al 1988) (Figure 2). Since 
it is prevented by a previous injection of the speciﬁ  c opiate 
antagonist naloxone, morphine- and methadone-induced pro-
lactin secretion seems to be primarily mediated by µ receptor 
(Panerai et al 1985; Shin et al 1988). To demonstrate whether 
an alternative dopamine independent mechanism, possibly 
involving a PRF, has a role in morphine-induced prolactin 
release in animals, complete blockade of dopaminergic recep-
tors was achieved by pre-treatment with pimozide, showing 
that morphine (10 mg/kg) was still able to stimulate prolactin 
release without any functional dopaminergic receptors. In 
conclusion, morphine stimulatory effect on prolactin release 
may act through a mechanism which is not depending on 
dopaminergic receptors (Shin et al 1988), though morphine, 
cocaine and beta-endorphine have been long reported to 
increase prolactin through dopaminergic interactions (Gold 
et al 1978). Long term methadone users have normal basal 
prolactin levels, even though a transient increase, beginning 
two-four hours after each daily dose, has been shown (Bart 
et al 2003).
H2-receptor antagonists
Although histamine H2-receptor competitive antagonists 
cimetidine and ranitidine, used in active ulcers, ulcer prophy-
laxis and gastric hypersecretory conditions, have stimulatory 
effect on prolactin secretion (Perret et al 1986; Knigge 1990), Therapeutics and Clinical Risk Management 2007:3(5) 946
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hyperprolactinemia has never been systematically reported, 
except for isolated case reports published shortly after the 
approval of the drugs (Petrillo et al 1977). The neurobe-
havioral syndrome, that appears with the withdrawal of H2 
receptors blockers and subsides with the restoration of the 
treatment or with the administration of a potent prolactin 
inducing drug as domperidone, should be related to a prompt 
reduction of prolactin levels (Rampello et al 1997).
In accordance with a histamine-dependent prolactin 
regulatory pattern, the histamine H2-receptor competitive 
antagonist cimetidine can have an inhibitory (following 
central administration) or stimulatory (following systemic 
administration) effect on prolactin secretion (Knigge 1990), 
the latter being the result of a decreased dopamine release 
from hypothalamus to pituitary gland (Morosini et al 1979). 
However, high doses of cimetidine possess an additional 
prolactin stimulatory action, not exerted by the other H2-
receptor antagonist ranitidine, that does not seem to be 
related to blockade of H2-receptors (Knigge 1990) nor to 
interaction with the dopaminergic system (Knigge et al 1987). 
The observation that systemic administration of speciﬁ  c 
histamine-H2 agonist (impromidine) is not able to avoid the 
cimetidine-induced prolactin release, while pre-treatment 
with benzodiazepines or GABA respectively suppressed or 
reduced prolactin response, suggested that cimetidine does 
not induce prolactin hypersecretion through an action on 
histamine H2 receptors, but through the interaction with 
other neurotransmitters, such as the pituitaric GABA-ergic 
system (Sibilia et al 1985) (Figure1).
Estrogens and anti-androgens
Estrogen-induced hyperprolactinemia is directly dependent 
on the degree of estrogenization. Physiologic amounts of 
estrogen in women cause a minimal increase in basal serum 
prolactin (Frantz 1978), but may explain the greater prolac-
tin response of women to physiologic and pharmacologic 
stimuli. Greater amounts of estrogens, as in pregnancy, 
increase basal prolactin concentration. It is uncertain whether 
the amount of estrogens in hormonal contraceptives is able to 
induce hyperprolactinemia: heterogeneous data concerning 
oral estroprogestinic anti-contraceptive therapy are reported. 
Studies on women taking low-dose-estrogen compounds 
(less than 50 micrograms of estradiol) did not show a signiﬁ  -
cant elevation response as compared to pretreatment levels 
(De Leo et al 1991) or control patients with intrauterine 
devices (Hwang et al 1986). In the studies documenting 
hyperprolactinemia, the incidence among women on oral 
contraceptives is variously reported, from 12% (Luciano et al 
1985) to 30% (Reyniak et al 1980). In the study by Luciano 
et al, hyperprolactinemia, assessed by multiple blood sampling, 
appeared transient and resolved spontaneously in about 50% 
of cases (Luciano et al 1985). In some of these studies, no 
correlation was found between the dosage of estrogenic 
component of the combined oral contraceptives, or duration 
of their use, and prolactin levels (Reyniak et al 1980; Davis 
et al 1984). Little is known, however, about dose-dependency of 
estrogen effects on plasma hormone levels. Hormone replace-
ment therapy is usually prescribed as medium- to high-dose 
formulations. In surgically or naturally menopausal women 
receiving different kinds of hormone replacement therapies, 
over 2 years and 6 months, no signiﬁ  cant differences in serum 
prolactin levels were found during subsequent treatment 
cycles, serum prolactin showing varying levels always within 
normal range (Foth and Romer 1997).
No increase in basal prolactin levels is reported during 
therapy with estrogen plus antiandrogen cyproterone acetate 
alone (Acien et al 1997) or with additional spironolactone 
(Kelestimur and Sahin 1998), nor during hirsutism treat-
ment with ﬂ  utamide (Muderris and Bayram 1999; Taner 
et al 2002). A signiﬁ  cant decrease in prolactin levels has been 
reported in patients treated with ﬂ  utamide alone (Akaza et al 
1993) or with ﬂ  utamide and an oral contraceptive formula-
tion with ethinyl estradiol and cyproterone acetate (Taner 
et al 2002). However, in 60 postmenopausal women receiv-
ing replacement therapy with estrogen plus anti-androgen 
cyproterone acetate, a signiﬁ  cant increase in hyperprolactin-
emic response to dopaminergic drug sulpiride was observed 
(Paoletti et al 2001), though normal basal prolactin levels 
were conﬁ  rmed.
Other drugs
Fenﬂ  uramine is a sympathomimetic amine used as an appetite 
suppressant. It causes hyperprolactinemia by promoting the 
release of serotonin and blocking its neuronal uptake, that 
leads to an increased serotoninergic activity and postsynaptyc 
stimulation of 5HT2A (Figure 2). In healthy subjects, pro-
lactin release by fenﬂ  uramine is dose-dependent, negatively 
correlated with age and increased in young females, as com-
pared to males (Newman 1998).
One case report documented hyperprolactinemia during 
chronic anticolvulsivant therapy with fenitoin and phenobar-
bital after the addition of oral ﬂ  uoresone 750 mg daily. The 
pathogenetic mechanism is unclear (Rossi et al 1983).
Hyperprolactinemia in four patients on protease inhibitors 
presenting with galactorrhea likely resulted from the enhance-
ment of dopamine antagonistic effects of other simultaneously Therapeutics and Clinical Risk Management 2007:3(5) 947
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administered drugs (prokinetics and fluoxetine) through 
inhibitory action on cytochrome P 450 system (Hutchinson et 
al 2000).
Cholinomimetic drugs with central effect, such as phy-
sostigmine, have been differently reported either to have 
no effect, to increase, or to inhibit prolactin release, though 
physostigmine may produce signiﬁ  cant increases in plasma 
prolactin concentrations in humans after intravenous infu-
sion. In three separate studies, reported by Risch et al 1982, 
conducted collaboratively by the National Institute of Mental 
Health and the University of California at San Diego, prolac-
tin rise following physostigmine and arecoline administration 
correlated with plasma concentrations of beta-endorphin 
immunoreactivity, cholinergic stimulation of hypothalamic 
beta-endorphin possibly representing an interesting example 
of peptidergic modulation of hypothalamic-pituitary hor-
monal regulation (Risch et al 1982).
Controversial data are available on the effect of chemo-
therapy and immunosuppression on prolactin levels. In a 
study of 20 women with breast cancer who underwent high-
dose chemotherapy and autologous blood stem-cell trans-
plantation, plasma prolactin levels increased signiﬁ  cantly 
during conditioning and within 30 days after transplant, 
remaining however within the normal age- and sex-adjusted 
range in all cases (Hinterberger-Fischer M et al 2000). In the 
same study (Hinterberger-Fischer MM et al 2000), the use of 
antiemetic drugs induced further increase in prolactin levels. 
However, this increase did not affect disease-free survival 
after transplant. These results are in line with those of previ-
ous studies that analyzed the long-term effect of allogeneic 
bone marrow transplantation on pituitary, gonad, thyroid and 
adrenal function in adult patients (Kauppila M et al 1998). 
Disturbances in GH, adrenal and prolactin were documented, 
but appeared to occur less frequently than functional impair-
ment of hypothalamus-pituitary-gonad/thyroid axis after 
intensive treatment and bone marrow transplantation 
(Kauppila M et al 1998a). Thus, it is very well known that 
chemotherapy induces frequently hypogonadism in both men 
and women by a direct toxic action on the gonad (Fairley KF 
et al 1972; Shamberger RC et al 1981), but signiﬁ  cant prolac-
tin increases are not frequent and are normally mild (Kauppila 
M et al 1998b). Hyperprolactinemia has been documented in 
the majority of patients treated with irradiation because of 
CNS malignancies (Constine LS et al 1987). In patients with 
CNS tumor, the risk to develop iatrogenic hyperprolactinemia 
is mostly dependent on the radiation dose, with the majority 
of subjects who receive more than 55 Gy experiencing this 
endocrine disturbance (Constine LS et al 1987), but is also 
dependent on the concomitant use of chemotherapy which 
increases the probability to develop both prolactin and thyroid 
abnormalities (Constine LS et al 1987).
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